

# Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 101 Insp GMP/IMP 101/19062596-0012[I]

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

### Part 1

Issued following an inspection in accordance with :

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : NOVARTIS PHARMACEUTICALS UK LIMITED

Site address : NOVARTIS PHARMACEUTICALS UK LIMITED, 2ND FLOOR, THE WEST WORKS BUILDING, WHITE CITY PLACE, 195 WOOD LANE, LONDON, W12 7FQ, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 101 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 01/05/2025 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

### Part 2

#### Human Investigational Medicinal Products

##### 1. MANUFACTURING OPERATIONS

###### [ 1.1 ] Sterile Investigational Medicinal Products

[ 1.1.3 ] Batch certification

###### [ 1.2 ] Non-sterile investigational medicinal products

[ 1.2.2 ] Batch certification

### [ 1.3 ] Biological investigational medicinal products

#### [ 1.3.2 ] Batch certification

##### [ 1.3.2.2 ] Immunological products

##### [ 1.3.2.3 ] Cell therapy products

##### [ 1.3.2.4 ] Gene therapy products

##### [ 1.3.2.5 ] Biotechnology products

##### [ 1.3.2.6 ] Human or animal extracted products

##### [ 1.3.2.8 ] Other biological medicinal products

Standard fermentation Biological Products

## 2. IMPORTATION OF MEDICINAL PRODUCTS

### [ 2.2 ] Batch certification of imported medicinal products

#### [ 2.2.1 ] Sterile Products

##### [ 2.2.1.1 ] Aseptically prepared

##### [ 2.2.1.2 ] Terminally sterilised

#### [ 2.2.2 ] Non-sterile products

#### [ 2.2.3 ] Biological medicinal products

##### [ 2.2.3.2 ] Immunological products

##### [ 2.2.3.3 ] Cell therapy products

##### [ 2.2.3.4 ] Gene therapy products

##### [ 2.2.3.5 ] Biotechnology products

##### [ 2.2.3.6 ] Human or animal extracted products

##### [ 2.2.3.8 ] Other biological medicinal products

Standard fermentation Biological Products

### [ 2.3 ] Other Importation Activities

#### [ 2.3.4 ] Other

1) The Importation of Radiopharmaceuticals/Radionuclide generators. 2) Importation of QP certified IMPs from a country on the approved country for import list.

### Restrictions or Remarks

This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. This certificate should be used in combination with the relevant authorisation/registration. A risk-based site inspection programme remains in force.

01/05/2025      Name and signature of the authorised person of the Competent Authority of United Kingdom  
Confidential  
Medicines and Healthcare products Regulatory Agency

MHRA-GMDP

MHRA

MHRA-GMDP

MHRA